Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
GREEN CROSS CORPORATION	YONGIN-SI GYEONGGI-DO 16924
MEDIGENEBIO CORPORATION	107 IHYEON-RO 30BEAON-GIL GIHEUNG-GU YONGIN-SI GYEONGGI-DO 446-855

International Classification(s)

• C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF

• 2015 Application Filing Year
• C12N Class
• 6649 Applications Filed
• 4472 Patents Issued To-Date
• 67.26 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Choi, Yong Woon	Yongin-si, KR	6	24
# of filed Patents : 6 Total Citations : 24
Chung, Yo Kyung	Yongin-si, KR	8	25
# of filed Patents : 8 Total Citations : 25
Jin, Thong-Gyu	Seoul, KR	9	24
# of filed Patents : 9 Total Citations : 24
Kim, Yong-Chul	Yongin-si, KR	67	500
# of filed Patents : 67 Total Citations : 500
Paik, Sang Hoon	Yongin-si, KR	14	89
# of filed Patents : 14 Total Citations : 89
Park, Yoo Chang	Yongin-si, KR	5	24
# of filed Patents : 5 Total Citations : 24
Seo, Jinwook	Yongin-si, KR	24	126
# of filed Patents : 24 Total Citations : 126
Son, Jong Mun	Yongin-si, KR	5	24
# of filed Patents : 5 Total Citations : 24

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 2 Citation Count
• C12N Class

• 53.01 % this patent is cited more than
• 9 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Nov 26, 2027

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2016/0145,589

COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF

---

Abstract

---

A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.